Omega Therapeutics is a biotechnology business based in the US. Omega Therapeutics shares (OMGA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $0.07 – an increase of 319.19% over the previous week. Omega Therapeutics employs 93 staff and has a trailing 12-month revenue of around $8.1 million.
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.07 |
|---|---|
| 52-week range | $0.01 - $3.63 |
| 50-day moving average | $0.38 |
| 200-day moving average | $1.16 |
| Wall St. target price | $11.50 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-1.32 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.081 from 2025-03-31
| 1 week (2025-03-26) | 370.93% |
|---|---|
| 1 month (2025-03-03) | 422.58% |
| 3 months (2025-01-03) | -90.36% |
| 6 months (2024-10-03) | -92.89% |
| 1 year (2024-04-02) | -97.31% |
|---|---|
| 2 years (2023-03-31) | -98.66% |
| 3 years (2022-04-01) | 6.58 |
| 5 years (2020-03-30) | N/A |
| Revenue TTM | $8.1 million |
|---|---|
| Gross profit TTM | $-34,498,000 |
| Return on assets TTM | -25.02% |
| Return on equity TTM | -166.9% |
| Profit margin | 0% |
| Book value | $0.21 |
| Market Capitalization | $7.9 million |
TTM: trailing 12 months
We're not expecting Omega Therapeutics to pay a dividend over the next 12 months.
You may also wish to consider:
Over the last 12 months, Omega Therapeutics's shares have ranged in value from as little as $0.01 up to $3.63. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Omega Therapeutics's is 1.644. This would suggest that Omega Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
To put Omega Therapeutics's beta into context you can compare it against those of similar companies.
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Steps to owning and managing MRK, with 24-hour and historical pricing before you buy.
Steps to owning and managing LLY, with 24-hour and historical pricing before you buy.
Steps to owning and managing ISRG, with 24-hour and historical pricing before you buy.
Steps to owning and managing VRTX, with 24-hour and historical pricing before you buy.
Steps to owning and managing MCK, with 24-hour and historical pricing before you buy.
Steps to owning and managing UNH, with 24-hour and historical pricing before you buy.
Steps to owning and managing AMGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABT, with 24-hour and historical pricing before you buy.
Steps to owning and managing PFE, with 24-hour and historical pricing before you buy.
Steps to owning and managing JNJ, with 24-hour and historical pricing before you buy.